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ORIGINAL ARTICLE
Latrepirdine is a potent activator of AMP-activated protein kinase
and reduces neuronal excitability
P Weisova´1,2,5, SP Alvarez1,3,5, SM Kilbride1,5, U Anilkumar1, B Baumann1, J Jorda´n3, T Bernas1,4, HJ Huber1, H Du¨ssmann1 and
JHM Prehn1
Latrepirdine/Dimebon is a small-molecule compound with attributed neurocognitive-enhancing activities, which has recently been
tested in clinical trials for the treatment of Alzheimer’s and Huntington’s disease. Latrepirdine has been suggested to be a
neuroprotective agent that increases mitochondrial function, however the molecular mechanisms underlying these activities have
remained elusive. We here demonstrate that latrepirdine, at (sub)nanomolar concentrations (0.1 nM), activates the energy sensor
AMP-activated protein kinase (AMPK). Treatment of primary neurons with latrepirdine increased intracellular ATP levels and glucose
transporter 3 translocation to the plasma membrane. Latrepirdine also increased mitochondrial uptake of the voltage-sensitive
probe TMRM. Gene silencing of AMPKa or its upstream kinases, LKB1 and CaMKKb, inhibited this effect. However, studies using the
plasma membrane potential indicator DisBAC2(3) demonstrated that the effects of latrepirdine on TMRM uptake were largely
mediated by plasma membrane hyperpolarization, precluding a purely ‘mitochondrial’ mechanism of action. In line with a
stabilizing effect of latrepirdine on plasma membrane potential, pretreatment with latrepirdine reduced spontaneous Ca2þ
oscillations as well as glutamate-induced Ca2þ increases in primary neurons, and protected neurons against glutamate toxicity.
In conclusion, our experiments demonstrate that latrepirdine is a potent activator of AMPK, and suggest that one of the main
pharmacological activities of latrepirdine is a reduction in neuronal excitability.
Translational Psychiatry (2013) 3, e317; doi:10.1038/tp.2013.92; published online 22 October 2013
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INTRODUCTION
Latrepirdine/Dimebon has been safely used as an anti-histami-
nergic agent for the treatment of allergies and travel diseases in
Russia for more than 25 years. Latrepirdine has been shown to
improve cognition in rodent models,1,2 and to enhance memory in
rhesus monkeys.3 Latrepirdine was also successfully tested in a
Phase 2 study of patients with mild-to-moderate Alzheimer’s
disease (AD).4 The potential mechanisms of latrepirdine’s
neurocognition-enhancing activities are unrelated to its anti-
histaminergic properties, and have been attributed to mito-
chondria-enhancing or -stabilizing activities.5,6 However, these
apparent ‘mitochondrial’ activities have been poorly characterized
at a molecular level. Despite this shortfall, latrepirdine was
subsequently tested in two Phase 3 trials in patients with AD,
and in a Phase 2/3 trial in patients with Huntington’s disease. All
three studies failed to observe any beneﬁcial activity of
latrepirdine when studied at a relatively advanced disease stage.7,8
Latrepirdine has been suggested to enhance or stabilize
mitochondrial membrane potential (Dcm), an important indicator
of mitochondrial function, in primary cortical neurons and human
SH-SY5Y neuroblastoma cells.5 Latrepirdine has also been shown
to increase cellular ATP levels, to protect SH-SY5Y cells against
serum starvation-induced cell death, and to reduce Ca2þ -induced
swelling of rat brain mitochondria.5,9 In the present study, we set
out to explore the potential mechanisms underlying the reported
mitochondrial activities of latrepirdine. We here describe that
latrepirdine is a very potent, small-molecule activator of the
intracellular energy sensor, AMP-activated protein kinase (AMPK),
acting at low, (sub-) nanomolar concentration ranges. We further-
more demonstrate that the molecular actions of latrepirdine
include profound changes on plasma membrane potential and
neuronal excitability, and investigate the conditions in which
latrepirdine may confer protection against excitotoxic neuronal
injury.
MATERIALS AND METHODS
Supplementary Information includes materials and a detailed description
of techniques not described in the main text.
Immunoﬂuorescence
As previously described,10 cerebellar granule neurons (CGNs) were
harvested from a 24-well plate using trypsin and ﬁxed in 1% formalin for
20–25min at 4 1C in the absence of a permeabilization step. Cells were
incubated with a rabbit polyclonal GLUT 3 antibody (Millipore Bioscience
Research Reagents, Billerica, MA, USA), diluted 1:250 in PBS and 0.1% BSA
for 1 h; cells were washed and incubated with an Alexa Fluor 488 goat
anti-rabbit IgG (H þ _L) antibody (Invitrogen, Biosciences, Dublin, Ireland)
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diluted 1:250 for 1 h. After washing the cells three times with PBS/0.1%
BSA, samples were analyzed immediately by ﬂow cytometry on a Partec
CyFlow ML (Mu¨nster, Germany) followed by analysis using FloMax
software. In all cases, a minimum of 104 events were acquired.
Preparation of primary CGNs
Murine or rat cerebellum was extracted from postnatal day 7–8 pups and
CGNs were prepared as described previously.11 Brieﬂy, cells were cultured
on poly-D-lysine-coated glass Willco dishes (Amsterdam, The Netherlands),
6-well plates and 24-well plates at a density of 1 106 cells per ml, or on
96-well plates (Corning) at a density of 50 000 cells per well in 100ml, and
maintained at 37 1C in a humidiﬁed atmosphere of 5% CO2/95% air.
Experiments were carried out after 7 days in culture when cells became
sensitive to glutamate excitotoxicity. All animal work was carried out with
ethics approval from the RCSI Research Ethics Committee and under the
licenses obtained from Irish government granted to the authors under the
Cruelty to Animal Act, 1976. A record of killed pups was taken down and
annual report was submitted to the Irish Department of Health and
Children.
Preparation of mouse neocortical neurons
Primary cultures of cortical neurons were prepared from E16 to E18 as
described previously.12 To isolate the cortical neurons, hysterectomies of
the uterus of pregnant female mice were performed using an abdominal
injection of 40mgkg 1 pentobarbital (Dolethal) as lethal anesthesia. The
cerebral cortices were pooled in a dissection medium on ice (PBS with
0.25% glucose and 0.3% bovine serum albumin). The tissue was incubated
with 0.25% trypsin–EDTA at 37 1C for 15min. After the incubation, the
trypsinization was stopped by the addition of medium containing sera. The
neurons were then dissociated by gentle pipetting, and, after centrifuga-
tion (300g for 3min), the medium containing trypsin was aspirated.
Neocortical neurons were then resuspended in fresh plating medium
(MEM containing 5% fetal calf serum, 5% horse serum, 100Uml 1
penicillin/streptomycin, 0.5mM L-glutamine and 0.6% D-glucose). Cells were
plated at 2 105 cells per cm2 on poly-lysine-coated plates and incubated
at 37 1C, 5% CO2. The plating medium was exchanged with 50% feeding
medium (Neurobasal medium embryonic containing 100Uml 1 Pen/
Strep, 2% B27 and 0.5mM L-glutamine) and 50% plating medium with
additional cytosine arabinofuranoside (600 nM). After 2 days, the medium
was again exchanged for complete feeding medium. All experiments were
performed on days in vitro 8–11. All animal work was performed with
ethics approval and under licenses granted by the Irish Department of
Health and Children.
Glutamate toxicity
After 7–8 days in culture, primary neurons were treated with glutamate/
glycine at concentrations of 100mM/10 mM for 10min in experimental buffer
composed of 120mM NaCl, 3.5mM KCl, 0.4mM KH2PO4, 5mM NaHCO3,
20mM HEPES, 1.2mM Na2SO4 supplemented with glucose (15mM) and
CaCl2 (1.2mM) at pH 7.4. Cultures were rinsed with 1.2mM
MgCl2-supplemented experimental buffer and returned to preconditioned
media.
Determination of neuronal injury
Cells cultured on 24-well plates were stained alive with Hoechst 33258
(Sigma) at a ﬁnal concentration of 1 mgml 1. Nuclear morphology was
imaged using an Eclipse TE 300 inverted microscope (Nikon) and a  20
dry objective. For each timepoint and treatment (glutamate/glycine,
100mM/10mM; latrepirdine 0.1–100 nM), cells were analyzed for apoptotic
morphology in three subﬁelds of each well (1000–2,000 cells per well) in a
blinded manner. All experiments were performed at least twice with
similar results.
Automated epiﬂuorescence analysis of Hoechst 33258 staining
and propidium iodide (PI) uptake using the Cellomics high-
content screening platform
To test the effects of a range of concentrations of latrepirdine against
glutamate excitotoxicity on a single-cell level, we used a Cellomics
ArrayScan VTI platform (Pittsburgh, PA, USA). The platform consists of an
automated epiﬂuorescence microscope connected to an automated plate
reader with temperature (37 1C) and CO2 control. CGNs seeded at density
105 per well were grown on a 96-well plate for 7 days and either
pretreated (for 24 h before glutamate treatment) or co-treated with a
range of concentrations of latrepirdine (0.01 nM100 nM). For quantiﬁca-
tion of cell death, neurons were double stained with low concentrations of
Hoechst 33258 (100 nM for 1 h before imaging) and PI (150 ngml 1
supplemented in culture media). Apoptotic and necrotic cells were
determined based on the intensity of Hoechst staining and nuclear
morphology. Hoechst-positive cells with large (or normal) nucleus and
PI negative were considered as healthy neurons, Hoechst positive
(high intensity) with condensed nuclei were considered as apoptotic
and Hoechst and PI positive with large (or normal) were considered as
necrotic. A  10 dry objective was used and nine subﬁelds within each
well (5000–6000 cells) were imaged at 60-min intervals over 24 h.
Dye concentration and image acquisition rate were optimized to
reduce phototoxicity. A 120-W metal halide lamp was for activation of
the ﬂuorophores. PI was excited at 545–575 nm; emission was collected
through a band pass of 590–625 nm. Hoechst was excited at 381–394
nm and emission light was collected through a 415–460 nm band pass
ﬁlter. Images were registered using a Hamamatsu Orca AG CCD and
digitized at 12-bit precision. Segmentation of cell nuclei was performed
on the Hoechst channel using locally adaptative Otsu thresholding,
implemented in Cell Proﬁler (http://www.cellproﬁler.org/). Quantiﬁcation
of apoptotic, primary necrotic and healthy cells was executed using a
CR&T classiﬁer (validated by a human expert), with nuclear area and
ﬂuorescence intensity (Hoechst and PI, average, s.d., min and max) serving
as the input.
shRNA and transfection of CGNs
Transfection of CGNs was performed at days in vitro 6 using the calcium-
phosphate-based transfection method as previously described.10 Brieﬂy, to
produce the DNA/CaPi coprecipitate, a mixture of CaCl2 solution, distilled
H2O, DNA plasmid solution (equivalent of 3 mg DNA), and 2 BBS (50mM
BES, pH 7.1 (N,N-bis[2-hydroxyethyl]-2-aminoethanesulfonic acid, 280mM
NaCl, 1.5mM Na2HPO4) was used. The transfection mixture was added to
the transfection medium (pH 7.65) in the culture dish. Cells were incubated
in a humidiﬁed incubator (without CO2) at 36.5 1C until the formation of
the DNA/CaPi coprecipitate. The cells were then washed with pre-warmed
(36.5 1C) Hank’s balanced saline solution (HBSS) washing buffer to ensure
that the precipitates have dissolved completely. Finally, cells were
incubated in conditioned neuronal tissue culture medium. shRNA
targeting ampk a1/a2 (pFIV-AMPK-shRNA) and scrambled sequence
(pFIV-Control-shRNA) were prepared and used as described previously.10
For inhibition of LKB1 and CaMKKb, neurons were transfected with a vector
(pGFP-V-RS) expressing either a commercial rat shRNA targeting lkb1 50-
TGGTGTCTGGATTCTCACTGAAGTCCTGT-30 (Gene ID 25048, Origene) or
camkkb 50-CCTGGAATCTTCCGACAGCACCAACACAA-30 (Gene ID 24245,
Origene, Rockville, MD, USA). Cells were used for experiments 48 h after
transfection. Efﬁciency of knockdown of AMPK, LKB1 and CaMKKb was
examined by western blotting.
Measurement of ATP
Cells were treated in 24-well plates, the medium was aspirated, 200ml of
hypotonic lysis buffer (Tris acetate buffer, pH 7.75) was added. Samples
were immediately stored at  80 1C. ATP measurements were performed
using the ENLITEN ATP assay system bioluminescence detection kit
(Promega, Southampton, UK) as per the manufacturer’s instructions.
Luminescence was recorded using a Tecan GENios well plate reader
(Ma¨nnedorf, Switzerland) in luminescence mode. ATP content values were
corrected for protein concentration determined using the Pierce BCA
micro protein assay kit, and normalized to vehicle-treated control samples.
The content of ATP was calculated by a concentration standard curve with
ATP levels normalized to protein content in each sample and expressed as
a percentage of the control.
Statistics
Data are given as means±s.e.m. For statistical comparison, one-way
analysis of variance between groups and Student-Newman-Keuls post hoc
test were carried out on SPSS software (SPSS GmbH Software, Munich,
Germany). Where the P-value waso0.05, groups were considered to be
signiﬁcantly different.
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RESULTS
Pretreatment with (sub)nanomolar concentrations of latrepirdine
provides neuroprotection against glutamate excitotoxicity
Excitotoxicity caused by glutamate receptor overactivation has
been shown to contribute to neuronal injury and neurodegenera-
tion in both acute and chronic neurodegenerative disorders,
including stroke, AD and Huntington’s disease.13–16 To
characterize potentially neuroprotective concentrations of
latrepirdine against glutamate excitotoxicity in high throughput
and at the single-cell level, we employed a Cellomics ArrayScan
high-content screening platform. This technique uses automated
epiﬂuorescence microscopy and allowed quantiﬁcation of effects
of latrepirdine on neuronal survival over a wide concentration
range over time within the same well plate. Because a previous
study has reported protective properties of latrepirdine against
serum starvation-induced cell death in SHSY-5Y neuroblastoma
cells in a pretreatment paradigm,5 we pretreated CGNs with
0.01–100 nM latrepirdine for 24 h. Latrepirdine was then washed
out and neurons exposed to excitotoxicity using a model of
glutamate-induced injury that has been extensively characterized
in our laboratory.10–12,17–20 We identiﬁed a narrow, (sub)-
nanomolar concentration window of around 0.1 nM, in which
latrepirdine conferred a protection against glutamate excito-
toxicity (Figure 1a).
We next veriﬁed the data obtained from the automated high-
content screening assay by manually scoring the percentage of
pyknotic nuclei. Pretreatment with latrepirdine (0.01, 0.1 and 1 nM)
for 24 h resulted in a signiﬁcant neuroprotection against gluta-
mate excitotoxicity, with the higher concentration of latrepirdine
(100 nM) showing no protective activity (Figure 1b), conﬁrming the
Cellomics data set. The concentration of latrepirdine that showed
most potent attenuation of cell death was 0.1 nM, thus we used
Figure 1. Latrepirdine pretreatment mediates neuroprotection against excitotoxic injury at (sub)nanomolar concentrations. (a) High-content
time-lapse screening of cell death following glutamate excitation. Murine cerebellar granular neurons plated in a 96-well plate were
pretreated with a range of concentrations of latrepirdine (0.01–100 nM) for 24 h as indicated. Cells were stained with Hoechst 1 h before
treatment with glutamate/glycine (for 10min at indicated concentrations) after which cells were washed twice with high Mg2þ buffer and
preconditioned medium (now containing PI) was replaced. The plate was then immediately placed within the Cellomics imaging chamber
(Time 0) and imaged at 1-h intervals over 24 h. Cells were categorized and analysis was carried out using Cell Profiler as described in the
Materials and Methods. Data presented are representative traces from thousand of cells, and experiments were carried out on three
independent neuronal cultures. (b) Murine cerebellar granular neurons were plated in 24-well plates and following pretreatment with
latrepirdine (0.01–100 nM as indicated) for 24 h, cells were exposed to glutamate/glycine 100 mM/10 mM for 10min. After treatment, cells were
washed twice with high Mg2þ buffer and incubated in preconditioned medium for a further 24 h. Pyknotic nuclei were counted as apoptotic,
as determined by Hoechst 33358 staining (1 mgml 1) and expressed as a percentage of total (n¼ 4 independent experiments in triplicate).
Data are presented as mean±s.e.m. *Pp0.001 indicates difference between glutamate-only treated and latrepirdine (0.01–1 nM)-pretreated
glutamate-treated neurons.
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this concentration of the compound for all further experiments.
Treatment with latrepirdine alone did not affect cell viability at any
concentration (Figure 1b). We then examined whether acute
treatment with Dimebon exerted any protective activity in the
context of glutamate toxicity. Interestingly, acute (10min)
pretreatment with latrepirdine (0.1 nM) failed to provide any
neuroprotection against glutamate excitoxicity (Supplementary
Figure 1). Collectively, these data suggest that Dimebon can act as
neuroprotectant against glutamate excitotoxicity when applied at
nanomolar concentrations and in a pretreatment paradigm,
however fails to provide any neuroprotection when added
concomitantly to excitotoxic stress.
Latrepirdine increases mitochondrial TMRM uptake
In light of previous ﬁndings that linked neuroprotective and
neurocognitive effects of latrepirdine to improved mitochondrial
bioenergetics,5,9,21,22 we next explored whether the protective
effects of latrepirdine pretreatment against glutamate toxicity
were related to changes in mitochondrial membrane potential
(Dcm), an indicator of mitochondrial bioenergetics. Neurons were
imaged by time-lapse confocal microscopy using the lipophilic,
cationic probe TMRM (10 nM) that is taken up into negatively
charged mitochondria, following Nernstian behavior, and is thus
also sensitive to changes in plasma membrane potential.17,23
TMRM uptake in single cells can be followed by time-lapse
microscopy and under non-quench conditions an increase in ﬂuo-
rescence intensity is indicative of increased uptake.17 Latrepirdine
increased mitochondrial TMRM ﬂuorescence intensity signiﬁcantly
after 60min (Figures 2a and b), in accordance with data previously
obtained in cortical neurons and SH-SY5Y cells.5 However, there
was no difference in TMRM ﬂuorescence intensity during exposure
to glutamate when compared to untreated neurons (Supple-
mentary Figure 2), suggesting that glutamate-induced membrane
potential depolarization is not affected by latrepirdine.
We next conducted a series of experiments to explore whether
the increase in TMRM uptake in response to latrepirdine was solely
due to changes in membrane potentials, or partially due to an
increase in mitochondrial mass or biogenesis. Neither the
expression level of the mitochondrial protein cytochrome c oxidase
subunit IV (COX IV) nor the total cellular ﬂuorescence intensity of
MitoTracker Green, a dye that is taken by mitochondria indepen-
dently of Dcm,
24 were altered in neurons treated with latrepirdine
(0.1 nM) for 24 h (Supplementary Figures 3 A and B). This suggested
that increased mitochondrial mass was not contributing to the
increase in TMRM uptake in response to latrepirdine. Furthermore,
the mRNA levels of two transcription factors involved in
mitochondrial biogenesis, the mitochondrial transcription factor A
(tfam) and peroxisome proliferator-activated receptor g coactivator
1a (pgc-1a), also remained unaltered in CGN cultures treated for
24h with latrepirdine (Supplementary Figure 3C).
Latrepirdine hyperpolarizes the plasma membrane potential (Dcp)
As well as responding to changes in mitochondrial membrane
potential (Dcm), TMRM ﬂuorescence intensity is also affected by
changes in plasma membrane potential (Dcp).
11,17,23,25 To
examine a possible contribution of plasma membrane potential
(Dcp) changes to the increase in TMRM uptake, CGNs were loaded
with the anionic, Dcp-sensitive probe DisBAC2(3) that is extruded
from cells upon Dcp hyperpolarization.
26 Interestingly, treatment
with latrepirdine (0.1 nM) induced a signiﬁcant decrease in DisBAC2(3)
ﬂuorescence intensity, indicative of Dcp hyperpolarization
(Figures 2c and d). Quantiﬁcation of DisBAC2(3) ﬂuorescence
intensities indicated a signiﬁcant decrease after 90min of
latrepirdine exposure, and decreasing further up to 240min after
drug addition (Figure 2e). These results indicated that the increase
in TMRM ﬂuorescence intensity in response to latrepirdine (0.1 nM)
may be attributable not only to changes in mitochondrial (Dcm)
but also to changes in plasma membrane potential (Dcp).
To elucidate more precisely the contribution of plasma
membrane potential changes to the TMRM signal kinetics, we
fed Dcp changes, calculated from average DisBAC2(3) ﬂuores-
cence intensity changes (Figure 2f), into a modiﬁed Nernstian
equation as described in Supplementary Materials (see also Ward
et al.17). The resulting trace is shown in Figure 2g. This approach
allowed us to correct TMRM kinetics for changes in Dcp kinetics
(Figure 2h). This analysis showed that the increase in TMRM
ﬂuorescence intensity following treatment with latrepirdine was
indeed attributable to changes in Dcp (Figure 2f).
Latrepirdine activates AMPK and affects neuronal bioenergetics
We have previously detected a direct link between increased
TMRM uptake, pre-conditioning, and activation of an evolutiona-
rily conserved metabolic sensor, AMPK.10,27,28 Moreover, a recent
study has demonstrated that AMPK activation leads to plasma
membrane hyperpolarization through phosphorylation of a
voltage-sensitive potassium channel.29 We therefore set out to
Figure 2. Latrepirdine increases TMRM fluorescence intensity and hyperpolarizes Dcp. (a) Representative single-cell traces of changes in TMRM
fluorescence intensity following latrepirdine treatment. Latrepirdine (0.1 nM) was added to cells on the confocal microscope stage and TMRM
fluorescence intensity was imaged at 5-min intervals over 240min. Analysis was carried out using Metamorph software and average pixel
intensity per cell at each timepoint is shown. (b) Quantification of average TMRM fluorescence intensity per cell at selected time points,
represented as mean±s.e.m. *Pp0.05, indicates the difference between 0min and 60, 120, 240min after latrepirdine addition (n¼ 65 cells).
This experiment was carried out on three independent cultures with similar results obtained. (c) Representative images of CGNs loaded with
DisBAC2(3) (1mM) and treated with latrepirdine (0.1 nM) on a confocal microscope stage showing decreased fluorescence intensity after
210min. DisBAC2(3) is a bis-barbituric acid oxonol compound that is incorporated into the plasma membrane as a function of Dcp. Plasma
membrane hyperpolarization is characterized as an extrusion of the probe with subsequent decrease in fluorescence, whereas depolarization
results in increased fluorescence. Scale bar, 10 mm. (d) The DisBAC2(3) traces from 105 cells treated with latrepirdine (0.1 nM) were averaged.
Neurons were treated with latrepirdine (0.1 nM) at 0min and fluorescence intensity imaged at 2-min intervals over 240min. Image analysis was
carried out as described in Supplementary Information. (e) Quantification of DisBAC2(3) (1 mM) fluorescence intensity (fl. int.) in vehicle-treated
versus latrepirdine (0.1 nM) treated CGNs from selected time points. Average DisBAC2(3) fluorescence intensity is represented as mean±s.e.m.
*Pp0.001, difference between vehicle-treated and latrepirdine-treated (0.1 nM) neurons stained with DisBAC2(3) (n¼ 105 cells). This
experiment was carried out on three independent cultures with similar results obtained. (f ) The corresponding Dcp values (in mV) for each
timepoint in the mean DisBAC2(3) traces were calculated as described in the Materials and Methods. (g) TMRM fluorescence intensity i)
reaches a stable baseline when the dye equilibrates across plasma and mitochondrial membranes and increased fluorescence intensity
corresponds to increased uptake driven by either ii) plasma membrane potential (Dcp) hyperpolarization or iii) mitochondrial membrane
potential (Dcm) hyperpolarization. (h) The kinetics of the mean TMRM intensity caused by changes in Dcp were calculated according to the
Nernstian equilibrium of the TMRM concentrations in the buffer, cytosol and mitochondria (see Materials and Methods for equations).
Thereby, it was calculated that the measured TMRM kinetics (blue line) indicated that there was a slight latrepirdine-induced depolarization of
the Dcm ( 1.6% at 240min), as the TMRM signal is lower than the expected increase due to the change in cytosolic TMRM after the
Dcp hyperpolarization.
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examine whether latrepirdine had a direct effect on the activity of
AMPK. Indeed, treatment of CGN cultures with latrepirdine
increased the levels of phospho AMPK (Thr 172), indicative of
elevated AMPK activity (Figures 3a and b).
Previous studies have identiﬁed enhanced glucose transporter 3
(GLUT 3) plasma membrane localization and elevated ATP levels in
response to AMPK activation in neurons.10,27 Therefore, we tested
whether latrepirdine treatment altered GLUT 3 translocation in
CGNs by examining GLUT 3 cell surface expression. Treatment of
neurons with latrepirdine (0.1 nM) led to a signiﬁcant increase
GLUT 3 translocation as evidenced by immunoﬂuorescence and
ﬂow cytometry analysis (Figures 3c and d). We also detected a
signiﬁcant increase in neuronal ATP levels after 24-h latrepirdine
treatment (Figure 3e), suggesting that Dimebon-induced AMPK
activation may enhance neuronal bioenergetic function or
decrease ATP utilization.
Latrepirdine-induced hyperpolarization of Dcp requires AMPK and
its upstream kinases LKB1 and CaMKKb
To assess whether increased AMPK signaling directly mediated
latrepirdine-induced changes in cellular physiology, we employed
small hairpin RNA (shRNA) technology to suppress AMPKa
expression 24 h before latrepirdine treatment as reported
previously (Figure 4a).10 Experiments were conducted using
TMRM uptake as read-out, and were evaluated on the single-cell
level as the shRNA contructs co-expressed GFP. Live-cell confocal
imaging microscopy of neurons with suppressed AMPKa (AMPKa
shRNA) revealed a complete suppression of latrepirdine-induced
alterations in TMRM uptake when compared with control shRNA-
transfected neurons (Figures 4b and c). Changes in DisBAC2(3)
ﬂuorescence intensity were also reduced in AMPKa shRNA-
transfected neurons (Figure 4d). We then addressed the question
as to whether the upstream AMPK kinases (AMPKK), LKB1 and
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CaMKKb30–32 could modulate the latrepirdine-induced changes in
TMRM uptake. Transfection of neurons with shRNA plasmids
targeting LKB1 (LKB1 shRNA) or CaMKKb (CaMKKb shRNA) also led
to a signiﬁcant depletion of neuronal LKB1 and CaMKKb levels
(Figure 4a). Gene silencing of either LKB1 or CaMKKb prevented
neuronal TMRM uptake in latrepirdine-treated neurons, suggest-
ing that the activity of both kinases was required for the
latrepirdine-induced increase in plasma membrane potential
(Figures 4b and c). We also pharmacologically inhibited AMPK
using the small-molecule inhibitor Compound C.10,12,33,34
Treatment with Compound C (10 mM) prevented the latrepirdine-
induced changes in DisBAC2(3) and TMRM (Figures 4e and f).
Collectively, these results suggested that the latrepirdine-induced
hyperpolarization of the plasma membrane potential required
AMPK.
Pretreatment with latrepirdine attenuates cytosolic Ca2þ inﬂux
during glutamate excitation and decreases spontaneous Ca2þ
elevations in neurons
Glutamate excitotoxicity is characterized by excessive Ca2þ inﬂux
through NMDA receptors, leading to intracellular Ca2þ overload.35
Indeed, glutamate-induced Ca2þ elevations critically depend both
on the magnitude of plasma membrane potential depolar-
ization,36 as well as ATP-dependent Ca2þ extrusion.37 Our
observations of plasma membrane hyperpolarization and the
changes in cellular bioenergetics in response to latrepirdine posed
the question whether protection by pretreatment with
latrepirdine may be mediated by reduced neuronal Ca2þ
overloading during glutamate excitation. CGN neurons were
pretreated with latrepirdine (0.1 nM), and changes in cytosolic
Ca2þ levels were monitored by confocal microscopy using Fluo-4
A.M. CGNs pretreated for 24 h with latrepirdine, and then exposed
to glutamate and glycine (100 mM/10mM for 10min) signiﬁcantly
attenuated cytosolic Ca2þ inﬂux (Figures 5a and b). Quantiﬁcation
of peak ﬂuo-4 ﬂuorescence (Figure 5b) during the glutamate
exposure showed a robust attenuation of Ca2þ inﬂux in CGN
neurons pretreated with latrepirdine (0.1 nM) for 24 h compared
with vehicle-pretreated neurons. This ﬁnding was furthermore
conﬁrmed by the observation that pharmacological activation of
AMPK with AICAR (0.1mM, 24 h before glutamate excitation) also
led to a signiﬁcant attenuation of cytosolic Ca2þ levels during
NMDA receptor overactivation in cortical neurons (NMDA alone:
5516.72 ± 1126.52 ﬂ. int. units, n¼ 70 cells vs. AICAR pretreated
3174.34±1152.78 ﬂuorescence intensity units, n¼ 67 cells,
Po0.001). Collectively, these data suggested that pharmacological
Figure 3. Latrepirdine induces AMPK activation and GLUT 3 translocation and increases ATP levels. (a) CGNs were treated with latrepirdine
(0.1 nM) and were lysed for protein quantification at indicated time points. The level of phosphorylated AMPK (Thr 172) relative to the total
level of AMPK, which corresponds to activation status of the enzyme, was examined by western blotting and (b) quantified using Image J (at
24-h timepoint post latrepirdine administration). This experiment was repeated three times with similar results. (c) Representative
immunofluorescence images of plasma membrane localization of GLUT 3 in vehicle and latrepirdine (0.1 nM)-treated neurons. Scale bar, 10mm.
(d) Quantification of GLUT 3 plasma membrane localization in vehicle and latrepirdine (0.1 nM)-treated CGNs by immunofluorescence by flow
cytometry. The mean fluorescence intensity of each population was obtained, and data are presented as mean±s.e.m. of n¼ 3 populations.
*Pp0.001 indicates difference between vehicle versus latrepirdine-treated neurons. This experiment was done in triplicate from 3
independent cultures. (e) CGNs were treated with latrepirdine (0.1 nM for 24 h), lysed and intracellular ATP content was determined as
described in Materials and Methods. Data are shown as mean±s.e.m. and the experiment was repeated on three independent preparations.
*Pp0.01 indicates difference between vehicle versus latrepirdine-treated neurons.
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AMPK activation with latrepirdine pretreatment affects Ca2þ
handling in primary neurons in response to glutamate excitotoxi-
city. Interestingly, acute pretreatment with latrepirdine (0.1 nM,
10min before glutamate) did not attenuate Ca2þ inﬂux
(Supplementary Figures 4A and B), suggesting that latrepirdine
did not act directly on glutamate receptors.
Figure 4. Inhibition of either AMPK activation or its upstream kinases (LKB1 and CaMKKb) abolishes the latrepirdine-induced increase in
TMRM fluorescence/decrease in DisBAC2(3). (a) Western blot analysis of CGNs transfected with short hairpin RNA (shRNA) directed against
AMPK a1/a2, LKB1 or CaMKKb versus a non-targeting shRNA (control shRNA) in respective experiments. Actin or tubulin served as loading
controls. The blots shown are representative of three independent experiments. (b) Representative single-cell traces of changes in TMRM
(10 nM) fluorescence intensity following latrepirdine treatment of neurons transfected with control shRNA, AMPKa shRNA, Lkb1 shRNA and
CamkB shRNA. Analysis was carried out using Metamorph software and average pixel intensity per cell at each timepoint is shown.
Only transfected, GFP-positive neurons were included in the analysis. (c) Quantification of TMRM fluorescence at indicated time points
(60, 120, 180 and 240min) post latrepirdine (0.1 nM) addition for neurons transfected with control shRNA (n¼ 86 cells), AMPKa shRNA (n¼ 47
cells), LKB1 shRNA (n¼ 60 cells) and CaMKKb shRNA (n¼ 61 cells). Data are shown as mean±s.e.m. *Po0.001 indicates difference between
control shRNA in timepoint 0min versus later time points after latrepirdine addition (60, 120, 180 and 240min). #Po0.001 indicates difference
between control shRNA neurons treated with latrepirdine (0.1 nM) versus neurons transfected with shRNAs directed against AMPK, LKB1 and
CaMKKb treated with latrepirdine. (d) Representative single-cell traces of changes in DisBAC2(3) (preincubated at 1mM for 30min at 37 1C)
fluorescence intensity following latrepirdine addition (0.1 nM) in neurons transfected with AMPK shRNA versus control shRNA. Analysis was
carried out using Metamorph software and average pixel intensity per cell at each timepoint is shown. Fluorescence intensity is represented as
mean±s.e.m. *Pp0.001 compared with group pretreated with vehicle. (e) Quantification of DisBAC2(3) (1 mM) fluorescence intensity (fl. int.)
in vehicle-treated (control) versus latrepirdine (0.1 nM)-treated CGNs from selected time points. Average DisBAC2(3) fluorescence intensity is
represented as mean±s.e.m. *Pp0.001, difference between control-treated and latrepirdine-treated (0.1 nM) neurons stained with DisBAC2(3)
(n¼ 78 cells). Effect of latrepirdine was abolished in neurons with inhibited AMPK activity (Compound C pretreatment 10 mM) marked as ns.
(f ) Quantification of TMRM fluorescence at indicated time points (0, 60, 120 and 240min). Neurons were pretreated with either
vehicle (control) or latrepirdine (0.1 nM) ± AMPK inhibitor Compound C (10 mM). Data are shown as mean±s.e.m. *Po0.01 indicates
difference between control and latrepirdine-treated neurons. This significance was abolished in neurons with inhibited AMPK activity
(Compound Cþ latrepirdine) marked as ns.
Latrepirdine activates AMPK and reduces neuronal excitability
P Weisova´ et al
7
& 2013 Macmillan Publishers Limited Translational Psychiatry (2013), 1 – 11
Having observed that latrepirdine activates AMPK and also
hyperpolarizes neuronal plasma membrane potential, we next
turned our attention to the effects of latrepirdine on neuronal
excitability, which was recently shown to be directly regulated by
AMPK activity.29 To address this, we measured spontaneous Ca2þ
oscillations in single-cortical neurons using high-frequency time-
lapse confocal microscopy. The addition of 0.1 nM latrepirdine
caused a signiﬁcant attenuation of spontaneous Ca2þ spiking in
the absence of Mg2þ compared to vehicle (Figure 5c). Quantiﬁca-
tion of the effect of latrepirdine showed an average reduction of
spiking frequency from 14.0±0.3 to 8.9±0.5min 1 (Figure 5d)
The frequency of spiking was signiﬁcantly lower in the presence of
Mg2þ (2mM), and addition of Tetrodotoxin (TTX, 1 mM) completely
abolished spontaneous Ca2þ spiking (Figure 5d). In accordance
with previous evidence indicating that activation of AMPK reduces
neuronal excitability,29 acute exposure of the cells to the AMPK
activator AICAR (0.1mM) reduced the Ca2þ -spiking frequency
from 13.8±0.1 to 6.1±0.7min 1 (Figure 5e). Direct comparison
of changes in frequency of oscillations induced by each
compound revealed that 0.1 nM latrepirdine reduced neuronal
excitability as potently as 0.1mM AICAR, as no signiﬁcant
difference was found between the two groups (Figure 5f).
DISCUSSION
Most of the current therapeutic strategies for the treatment of AD
are designed to target NMDA receptor overactivation, or to target
b amyloid itself by interfering with its synthesis, aggregation or
Figure 5. Latrepirdine pretretment attenuates the increase in cytosolic Ca2þ during glutamate excitation and reduces spontaneous Ca2þ
oscillations. (a) Average single-cell traces of changes in fluorescence intensity of the cytosolic Ca2þ indicator Fluo-4 AM in response to
glutamate excitation. CGNs pretreated with latrepirdine (0.1 nM for 24 h were loaded with Fluo-4 AM (3mM) and mounted on the confocal
microscope stage. Glutamate excitation (glutamate/glycine [100 mM/10 mM] for 10min immediately followed by addition of MK 801 [2.5 mM])
was induced as indicated. Analysis was carried out using Metamorph software and average pixel intensity per population at each timepoint is
shown. (b) Quantification of area under the Fluo-4 AM curve during glutamate excitation in prolonged latrepirdine-pretreated neurons.
Vehicle: n¼ 30 cells; latrepirdine: (n¼ 45 cells). Data are shown as mean±s.e.m. *Po0.001 compared with vehicle-pretreated neurons that
were glutamate treated. (c) Murine cortical neurons were cultivated on glass bottom dishes, incubated with 5mM Fluo-4-AM for 45min at 37 1C,
washed, perfused with experimental buffer supplemented with 2mM MgCl2 and placed on the heated stage of a LSM 5live microscope.
Images were taken at 5Hz, optical slice thickness set to 3.5 mm. The buffer was replaced with MgCl2-free buffer at time 0 and either vehicle or
latrepirdine (0.1 nM) was added after 120 s of imaging as indicated. Typical Fluo-4 kinetics are shown as change in fluorescence intensity
divided by the mean overall fluorescence intensity (DF/F). (d) Quantification of Ca2þ spike frequency after MgCl2 washout, treatment with
latrepirdine (0.1 nM, n¼ 176 cells) or (e) AICAR (0.1mM) (n¼ 88 cells) addition followed by complete block using tetrodotoxin (TTX, 1 mM)
(significant difference Po0.05, paired t-test). (f ) Quantification of changes of the Ca2þ -spiking activity due to addition of latrepirdine, AICAR,
or vehicle (Control, n¼ 134 cells, latrepirdine, n¼ 176 cells, AICAR n¼ 88 cells, Kruskal–Wallis and subsequent Mann–Whitney tests showed a
significant difference in latrepirdine and AICAR compared with control (*) but no significant difference in latrepirdine compared with AICAR
(ns).
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degradation. Latrepirdine has gained signiﬁcant interest as a novel
class of therapeutic agents that target ‘mitochondria’, but has
subsequently failed in clinical trials. We here demonstrate that
latrepirdine is an activator of the energy sensor, AMPK, acting at
surprisingly low, (sub-) nanomolar concentrations. We furthermore
describe that the pharmacological activities of latrepirdine in
primary neuron cultures include a pronounced effect on Dcp, and
a strong inhibitory effect on neuronal excitability and glutamate-
induced Ca2þ increases.
During conditions of increased energy demand, AMPK is
activated as a protective response in an attempt to restore
cellular homeostasis.28 Our ﬁndings that latrepirdine activates
AMPK is in agreement with previous studies that demonstrated
that latrepirdine improves neuronal energy metabolism38 and
mitochondrial function.5,22 Supporting these ﬁndings, we
demonstrate that latrepirdine triggers an increase in GLUT 3
translocation that was coupled with an increase in neuronal ATP
levels. Latrepirdine has previously been shown to enhance
cerebral glucose utilization in aged mice in vivo.39 We also
observed that latrepirdine treatment led to a pronounced increase
in mitochondrial uptake of the cationic dye, TMRM, suggestive of
Dcm hyperpolarization.
17 This effect was abrogated in neurons in
which AMPKa expression was silenced, demonstrating the
requirement of AMPK for the effect of latrepirdine on mito-
chondrial TMRM uptake. However, TMRM uptake into cells is
determined by the Nernst potential across both plasma and
mitochondrial membranes.11,25 Subsequent experiments indicated
that latrepirdine also induced a strong Dcp hyperpolarization. It is
important to mention in this context that AMPK has previously
been shown to hyperpolarize Dcp through the phosphorylation of
a voltage-sensitive potassium channel.29 Indeed, further
quantitative analysis demonstrated that Dcp hyperpolarization
largely contributed to the latrepirdine-induced increased in TMRM
uptake, precluding a pure ‘mitochondrial’ action of latrepirdine. As
the plasma membrane Naþ /Kþ ATPase uses at least 50% of
neuronal ATP to maintain resting Dcp,
40 a Dcp hyperpolarization
may also indirectly preserve cytosolic ATP expenditure, and thus
may contribute to the increase in cellular ATP levels in response to
latrepirdine treatment as observed in this and previous studies.
Our study also demonstrated that treatment with latrepirdine
reduced glutamate-induced and ‘spontaneous’ cytosolic Ca2þ
elevations, indicating that the latrepirdine-induced hyperpolariza-
tion of Dcp correlated with decreased neuronal excitability. We
noted a strong inhibition of glutamate-induced Ca2þ elevations
following latrepirdine pretreatment, but not during acute treat-
ment, suggesting that latrepirdine does not directly inhibit NMDA
or other glutamate receptors. The inhibitory effect of latrepirdine
pretreatment on glutamate-induced Ca2þ elevations could be
due to plasma membrane potential hyperpolarization limiting
NMDA receptor activation, or due to an improvement of neuronal
ATP levels, enabling a faster removal of cytosolic Ca2þ via plasma
membrane ATPases or the Naþ /Kþ -ATPase-driven Naþ /Ca2þ
exchanger. It is also possible that latrepirdine pretreatment alters
NMDA receptor function or expression, however this requires
further detailed investigation. We also found that latrepirdine
potently reduced spontaneous Ca2þ spiking in cultured cortical
neurons, ﬁndings that are compatible with the pronounced
hyperpolarizing effect of latrepirdine on Dcp. Latrepirdine’s
inhibition of glutamate-induced Ca2þ elevations and neuronal
excitability is also of interest in the context of the failed clinical
trials of latrepirdine in AD patients. While NMDA receptor
hyperactivity has been suggested to be associated with AD, it is
likewise accepted that sufﬁcient NMDA receptor activity requires
to be maintained to exert a beneﬁcial effect in AD patients.41
While we observed a signiﬁcant protective effect of prolonged
latrepirdine pretreatment against glutamate excitotoxicity, acute
pretreatment with latrepirdine failed to provide protection. Nor
did acute pretreatment attenuate the glutamate-induced increase
in cytosolic calcium, indicating that calcium inﬂux may be the key
signaling event that precipitates excitotoxic cell death. Prolonged
pretreatment with latrepirdine activated AMPK, a kinase with both
pro-survival,10,42 but also cell death-inducing activities.28 Our data
demonstrate that there is a narrow range of latrepirdine
concentrations that can exert a protective effect against
excitotoxicity. This may reﬂect the moderate activation of AMPK
within a pro-survival range, above which pro-death signaling
occurs. We have recently shown that excessive or prolonged
AMPK activation can lead to cell death through upregulation of
pro-apoptotic BH3-only protein expression.12,43,44 McCullough
et al.45 identiﬁed that continuous activation of AMPK increased
neuronal injury during ischemia. Activation of AMPK has also been
shown to potentiate neurodegeneration of striatal neurons in a
mouse model of Huntington’s disease.46 On the other hand, AMPK
activation has been shown to promote pro-survival signaling, and
latrepirdine has recently been shown to stimulate autophagy and
reduce the accumulation of a-synuclein in vitro and in vivo,47 to
enhance mTOR- and Atg5-dependent autophagy and to arrest
progression of neuropathology in an AD mouse model.48 Our data
suggest that AMPK activation by latrepirdine may underlie the
reported effects of latrepirdine on autophagy-mediated clearance
of protein aggregates in such disease models. Indeed, induction of
autophagy through AMPK-activating compounds has been shown
before to enhance the clearance of both soluble and aggregated
forms of Ab and tau proteins in vivo and in vitro.49 However, as
AMPK may already be abnormally activated in symptomatic AD,50
effects of AMPK activators such as latrepirdine on AD
pathogenesis may strongly depend on disease progression. The
experimental paradigm employed in our study naturally differs
from the chronic exposure paradigm used in earlier clinical trials.
Nevertheless, our in vitro data carefully argue for a potentially
beneﬁcial effect of latrepirdine in early AD, rather than at an
advanced disease stage. Likewise, latrepirdine may be effective in
individuals at risk of developing neurodegenerative disorders
when given pre-symptomatically, for example, in familial forms of
neurodegenerative disorders.
AMPK is considered a key sensor of the cellular energy status.
AMPK signaling regulates energy balance at the cellular, organ
and whole-body level.10 Our ﬁndings that latrepirdine activates
AMPK, and that the activation of AMPK by latrepirdine requires the
upstream kinases LKB1 and CaMKKb, shed new light into the
mechanism of action of latrepirdine. Knockdown of either LKB1 or
CaMKKbeta, the upstream kinases that activate AMPK, prevented
the latrepirdine-induced increase in plasma membrane potential.
This indicates latrepirdine may act upstream of both of these
kinases to induce hyperpolarization. CaMKKbeta is thought to
activate AMPK in response to increased levels of intracellular
calcium concentration,31 whereas LKB1 is required for maintaining
baseline AMPK phosphorylation levels.51 Although we show that
latrepirdine reduced the amplitude of spontaneous calcium
oscillations, we did not observe an increase in overall intra-
cellular calcium per se on addition of latrepirdine. This suggests
that the effects of latrepirdine on AMPK phosphorylation are
independent of the effects on calcium. Thus, the activation of
AMPK may result from latrepirdine activity at sites upstream of
AMPK itself. In accordance with this hypothesis, treatment with
latrepirdine progressively increased AMPK activity over 24 h, and
hyperpolarization of Dcp also continued to occur for the duration
of the 4-h experiment. However, treatment with latrepirdine
immediately attenuated Ca2þ oscillations, indicating that
latrepirdine has direct effects on proteins involved in neuronal
Ca2þ dynamics. Therefore, further molecular and structural
studies will be required to determine precise targets and
binding sites. Nevertheless, the observation that 0.1 nM
latrepirdine activates AMPK indicates that this compound is
one of the most potent pharmacological activators of AMPK
described so far.
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